Genome Engineering and iPSC Center (GEiC)


Xiaoxia Cui, PhD
Jeffrey Milbrandt, MD, PhD


The goal of the Genome Engineering and Induced Pluripotent Stem Cell Center is to speed scientific discovery through the rapid and precise modification of genomes. Genome engineering uses custom endonucleases to create targeted double-strand breaks in genomic DNA. The repair of these DNA breaks by the natural cellular repair machinery can lead to targeted, user defined genomic modifications enabling unprecedented abilities to study genetic variation and to manipulate cells for research and therapeutic purposes. Induced pluripotent stem cell (iPSCs) have the potential to develop into all tissues and organs and therefore open new research avenues for disease modeling. Skin fibroblasts or renal epithelial cells from urine can be reprogrammed into iPSCs, which in turn can be differentiated into specific cell type to study pathogenesis. The GEiC provides access to these technologies for cancer researchers.

LOCATION: 4515 McKinley Building

PRICING: Please contact the core for current pricing of services offered.

TO ACCESS: Xiaoxia Cui at, 314-362-2906

NIH PUBLIC ACCESS POLICY: As of April 7, 2008, the NIH requires investigators with a publication using Siteman (or other NIH-funded) shared resources to submit (or have submitted for them) their final, peer reviewed manuscripts to PubMed Central(PMC) upon acceptance of publication, to be made publicly available within 12 months of publication. Many journals automatically submit these for authors, but Washington University also has assistance available through the Becker Medical Library. Please see or for more information.

PUBLICATION ACKNOWLEDGEMENT: If research supported by the Genome Engineering and Induced Pluripotent Stem Cell Center results in publication, please acknowledge this support by including the following in your publication(s):

We thank the Alvin J. Siteman Cancer Center at Washington University School of Medicine and Barnes-Jewish Hospital in St. Louis, MO., for the use of the Genome Engineering and Induced Pluripotent Stem Cell Center, which provided __________ service. The Siteman Cancer Center is supported in part by an NCI Cancer Center Support Grant #P30 CA091842.